Compare IFRX & UTMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IFRX | UTMD |
|---|---|---|
| Founded | 2007 | 1978 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 225.5M | 216.1M |
| IPO Year | 2017 | 1994 |
| Metric | IFRX | UTMD |
|---|---|---|
| Price | $1.05 | $70.98 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $8.29 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 22.0K |
| Earning Date | 11-03-2026 | 10-22-2026 |
| Dividend Yield | N/A | ★ 1.78% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 2.54 |
| Revenue | N/A | ★ $38,520,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $27.99 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $53.80 |
| 52 Week High | $2.95 | $76.89 |
| Indicator | IFRX | UTMD |
|---|---|---|
| Relative Strength Index (RSI) | 27.04 | 40.37 |
| Support Level | $0.81 | $67.40 |
| Resistance Level | $1.07 | $73.03 |
| Average True Range (ATR) | 0.15 | 1.74 |
| MACD | -0.02 | -0.11 |
| Stochastic Oscillator | 0.00 | 1.72 |
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable, and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, and Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals, and outpatient clinics and physicians' offices.